anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
ETHNOPHARMACOLOGICAL RELEVANCE: Pueraria lobata (Willd.) Ohwi is a traditional medicinal and edible homologous plant rich in flavonoids, triterpenes, saponins, polysaccharides and other chemical components. At present, studies have shown that Pueraria lobata radix (PR) has the effect of lowering blood sugar, improving insulin sensitivity and inhibiting obesity. However, the specific mechanism of PR inhibits obesity is still unclear, and there are few researches on the anti-obesity effect of PR through the combination of network pharmacology and experiment.
AIM OF THE STUDY: Pharmacology, molecular docking technology and experimental verification through the network, revealing the PR the material basis of obesity and the potential mechanism.
METHODS AND RESULTS: The present study used network pharmacology techniques to investigate the therapeutic effect and mechanism of action of PR. Through relevant databases, a total of 6 main chemical components and 257 potential targets were screened. Protein interaction analysis shows that AKT1, AKR1B1, PPARG, MMP9, TNF, TP53, BAD, and BCL2 are core targets. Enrichment analysis shows that the pathway of PR in preventing obesity involves the cancer signaling pathway and the PI3K-Akt signaling pathway, which may be the main pathways of action. Further molecular docking verification indicates that its core target exhibits good binding activity with 4 compounds: formononectin, purerin, 7,8,4 '- trihydroxide and daidzein. Using the ultra-high performance liquid chromatography-mass spectrometry (UPLC-MS) technology to detected and confirmed these main compounds. Cell experiment results revealed that puerarin inhibits cell proliferation and differentiation in a concentration dependent manner, significantly promoting cell apoptosis and affecting cell migration. Animal experiments have shown that puerarin reduces food intake and weight gain in mice. It was found that puerarin can upregulate HDL and downregulate TC, TG, and LDL blood biochemical indicators. Western blot results showed that puerarin significantly inhibited the expression of AKT1, AKR1B1, MMP9, TNF, TP53, BCL2, PPARG, and significantly increased the expression of BAD protein at both cellular and animal levels.
CONCLUSION: The present study established a method for measuring PR content and predicted its active ingredients and their mechanisms of action in the treatment of obesity, providing a theoretical basis for further research.
A new and improved clinical critical care path system, which can be tailored readily for a given patient diagnosis for either single or combined medical and/or surgical diagnoses. The clinical information system stores critical care information for various patient diagnoses and retrieves them for a given patient. Treatment information is tailored to a given patient by enabling selected treatment information to be edited. Where multiple diagnoses are present, the prescribed or ordered treatment plans for each diagnosis are merged for a given patient, and potential conflicts are determined for any ordered activity. Upon determination of a conflict, patient treatment information is repeated on separate display lines to alert the healthcare provider to permit the healthcare provider to analyze the conflict and to determine what order or orders should be entered. Customized multiple diagnosis treatment information can then be entered and stored for a given patient.
PURPOSE:To enhance workability and compression strength and to facilitate the unification with the bone tissue or teeth tissue of a living body, by compounding alkali metal salt or ammonium salt of citric acid with at least one of an alpha-tricalcium phosphate powder and a curing liquid. CONSTITUTION:This curable composition is composed of an alpha-tricalcium phosphate powder or a powder agent consisting of said powder and a barium sulfate powder and a curing liquid, and alkali metal salt or ammonium salt of citric acid is compounded with at least one of the aforementioned powder agent and the aforementioned curing liquid. The use amount of barium sulfate is 5-30wt.%, pref. 10-20wt.% of the alpha-tricalcium phosphate in order to improve not only X-ray imaging property but also kneading workability. As the curing liquid, especially, an aqueous solution of a homopolymer or copolymer of unsaturated carboxylic acid, an aqueous citric acid solution or a solution mixture thereof can be pref. used because excellent compression strength is imparted to a cured substance. The concn. of the aqueous solution is pref. within a range of 10-60wt.%.
Disclosed are chimeric antigen receptors (CAR) specific to αvβ6 integrin which is uniquely expressed in a wide variety of cancers. Also disclosed are vectors to express the CAR and methods to use the CAR to treat patients suffering from cancer. The instant disclosure provides a CAR comprising a binding domain specific to αvβ6 integrin. In various exemplary embodiments, the αvβ6 specific binding domain comprises a sequence as defined by SEQ ID NOs. 1-12. In some embodiments, the CAR comprises one or more intracellular domains comprising 4-1 BB domain, CD3ζ domain, and CD28 domain. In some embodiments, the αvβ6 binding domain is fused to an Fc region by a glycine-serine linker. In these and other embodiments, the Fc region is substantially similar to an IgG4 or an IgG1 Fc region.
A cancer treatment composition that includes natural substances. The cancer treatment composition functions by inhibiting growth and formation of cancer cells by inhibiting specific pathways. Specifically, the composition provides a combination of Wnt signaling pathway inhibitors and histone deacetylase inhibitors. Preferably, the composition includes therapeutically effective amounts of dimethoxycurcumin and/or quercitin for inhibiting the Wnt signaling pathway, and honokiol and royal jelly for inhibiting histone deacetylase. The composition may further include one or more antitumorigenic compounds such as graviola guanabana, lyceum barbarum, gogi, red reishi, and salvestrol, among others. Thus, the present invention provides a cancer treatment composition having natural substances and compounds.
Nalmefene hydrochloride injection prevents or reverses the effects of opioids, including respiratory depression, sedation, and hypotension. Pharmacodynamic studies have shown that Nalmefene hydrochloride injection has a longer duration of action than naloxone at fully reversing doses. Nalmefene hydrochloride injection has no opioid agonist activity.

Nalmefene hydrochloride injection is not known to produce respiratory depression, psychotomimetic effects, or pupillary constriction. No pharmacological activity was observed when nalmefene hydrochloride injection was administered in the absence of opioid agonists.

Nalmefene hydrochloride injection has not been shown to produce tolerance, physical dependence, or abuse potential.

Nalmefene hydrochloride injection can produce acute withdrawal symptoms in individuals who are opioid dependent.
Teprotumumab administered q3W by IV infusion over a period of 24 weeks for a total of 8 infusions. All participants start treatment at a dose of 10 mg/kg. At Week 3, the dose is escalated to 20 mg/kg and kept constant for the remainder of the study.
A system of validating self-administration of prescription medication by a patient wherein the prescription medication is administered over a series of timed dosages. A machine-readable optical code label such as a QR Code is affixed to an interior surface of a prescription medication container containing the prescribed medication such as the interior of the bottle cap. The container must be open to electronically read the optical code label. The label contains data associated with the prescription medication and is read by a software application installed on a smartphone. The software receives the label-embedded data and a timestamp to validate the patient is self-administering the prescription medication consistent with the series of timed dosages. An alert notification is automatically generated to a healthcare administrator responsive to a deviation in the series of timed dosages.
Kaledo game, which is a board game, has been developed to inform children about healthy eating. The aim of this game is to teach children calorie balance through the calorie values of foods. Kaledo game gives children the opportunity to stay motivated and have fun. While children are having fun, they also gain the knowledge necessary for healthy eating behavior change. The game is played with 2-4 people. A game session takes 15-30 minutes Children in the playgroup played 15-30 minutes (1 round) Kaledo game every week for 12 weeks.
The primary aim of the proposed research is to evaluate the feasibility of a socio-cognitive-behavioral therapy protocol for suicidal behavior (SCBT-SB) with Latino/a adolescents in comparison to treatment as usual (TAU). The SCBT-SB protocol was develop in Puerto Rico, but was expand to Latinx populations in U.S. based on a previous qualitative study. The SCBT-SB include developmental and cultural factors in order to optimize treatment outcomes in suicidal Latino/a adolescents. Study design: A pilot randomized controlled trial (RCT) of the SCBT-SB versus TAU was conducted in a real world scenario. Participants were 46 Latino/a adolescents (13-17) admitted to a Psychiatric Unit for suicide ideation or suicide attempts, who were referred to outpatient care, and at least one legal guardian. RCT's primary question is: Is the SCBT-SB protocol feasible in terms of satisfaction, acceptability, recruitment, retention, and therapist adherence? RCT's secondary question is: What is the magnitude of difference in suicidality and psychopathology symptoms between the SCBT-SB and the TAU at three, six, and 12 months following baseline?
Phase I The study will plan to enroll 3 patients in an initial cohort, to receive the dose level 1 of lenalidomide (10 mg PO) on days 1-14 of a 21-day cycle, and pembrolizumab (200 mg IV) on day 1. Patients will be evaluated for toxicities after initiation of treatment. If there are no DLTs for the initial 3 patients after one cycle, the next dosing cohort will open, with another 3 patients. Similarly, if the second cohort of patients receives the dose level 2 of lenalidomide (15 mg) for one cycle without DLT, then the third and final cohort will open. When the third cohort testing the dose level 3 of lenalidomide (20 mg) has completed one cycle, the phase I component of the trial will be completed. Standard phase I, 3 + 3 design rules will be utilized as follows: if 1 out of 3 patients experiences a DLT at certain dose level, then 3 more patients will be enrolled at the same level. If 2 out of 6 patients experience DLT at a certain dose level, 3 additional patients are added at the next lower level. Dose reduction is continued until at most 1 of 6 patients experiences DLT. The highest level with at most 1 of 6 patients DLT will be declared MTD. If no dose level achieves this criterion the trial will be discontinued for excess toxicity.

Phase II A pre-treatment (archival) and fresh tumor sample will be needed for participation in trial. PD-L1 expression levels in both samples will be determined to assess the role of chemotherapy on expression level and pattern of this biomarker. Baseline blood samples will be collected for immunologic correlates prior to treatment on Day 1 of Cycle 1 and post treatment at 2, 4, 24 hours. Samples will also be collected prior to treatment on Day 1 of Cycle 2, and at time of progression. Baseline CT scan of the chest and abdomens will be obtained within 30 days prior to the initiation of cycle 1. CT scan with contrast or MRI with contrast of the brain will also be obtained within 30 days prior to the initiation of cycle 1. Time to progression will be measured with disease imaging following every 2 cycles of therapy with a three-day window (+ or -). Patients will continue treatment until disease progression or unacceptable toxicity or two years of therapy. Overall survival will be assessed every 3 months during long term follow up
LMA will be inserted with the initial inflating volume correspondent to residual volume group ( RV group): volume result of equilibrating pressure between intracuff pressure and atmospheric pressure. A 20 ml syringe without plunger is connected to the laryngeal cuff for 5 minutes.
Following a 7 day run-in period in which participants take placebo twice a day (BID), participants are randomized to the cohort that will take XP19986 SR1 10 mg BID treatment crossing over to placebo treatment (or the reverse order). Each treatment segment follows the same pattern: 3-9 days of titration, 7 days at target dose, 3-9 days of tapering, followed by a 3-day placebo washout.
A silver-free, gold-palladium dental alloy contains (by wt.) 3-10% In and 1-4% Ru. When the alloy is to receive a fired ceramic coating, it pref. contains 1% Sn. Pref. when the alloy contains 10% In then it contains 3.5% Ru. Compared with the alloy of DE2814943 the alloy does not contain Ga (which hinders prodn. of oxide-free, dense castings) and Sn (which causes embrittlement and makes the alloy less useful e.g. for dental bridges) as hardening components. Only a small amt. of Sn, as adhesion promoter, is required in alloys which receive a fired ceramic coating. The alloy is suitable for receiving various types of ceramic coatings since only the Au and Pt contents have to be varied to match thermal expansion coeffts. and this variation does not affect the mechanical properties of the alloy. Specification printed 25.2.82.
Beta-hydroxybutyrate (BHB) mixed salts are formulated to induce or sustain ketosis in a subject. The BHB mixed salts provide a biologically balanced set of cationic electrolytes and avoid detrimental health effects associated with imbalanced electrolyte ratios. BHB mixed salt compositions include two, three or four of sodium BHB, potassium BHB, calcium BHB, or magnesium BHB. BHB mixed salt compositions include R-BHB and/or S-BHB, such as enriched with either R-BHB or S-BHB. BHB mixed salt compositions may include BHB mixed salts and beta-hydroxybutyric acid. BHB mixed salts may be provided as or mixed with a dietetically or pharmaceutically acceptable carrier. BHB mixed salt compositions can be a solid, such as a powder, or a liquid, such as a beverage. A mixed salt-acid composition is particularly well-suited for flavored beverages.
BACKGROUND: With over 7000 Mendelian disorders, identifying children with a specific rare genetic disorder diagnosis through structured electronic medical record data is challenging given incompleteness of records, inaccurate medical diagnosis coding, as well as heterogeneity in clinical symptoms and procedures for specific disorders. We sought to develop a digital phenotyping algorithm (PheIndex) using electronic medical records to identify children aged 0-3 diagnosed with genetic disorders or who present with illness with an increased risk for genetic disorders.
RESULTS: Through expert opinion, we established 13 criteria for the algorithm and derived a score and a classification. The performance of each criterion and the classification were validated by chart review. PheIndex identified 1,088 children out of 93,154 live births who may be at an increased risk for genetic disorders. Chart review demonstrated that the algorithm achieved 90% sensitivity, 97% specificity, and 94% accuracy.
CONCLUSIONS: The PheIndex algorithm can help identify when a rare genetic disorder may be present, alerting providers to consider ordering a diagnostic genetic test and/or referring a patient to a medical geneticist.
Older people in this group will perform aerobic and resistance training for 1 hour a day, twice a week for ten weeks, under the supervision of a researcher physiotherapist. As for Inspiratory Muscle Training, they will participate in training with 30 breathing cycles a day, six days a week, for ten weeks (two days in the clinic, four days at home).
<P>PROBLEM TO BE SOLVED: To provide a live and inactivated Chicken Anaemia Agent (CAA) vaccine capable of inducing an immune response in a vaccinated chicken.  <P>SOLUTION: The CAA virus of the vaccine is attenuated by the serial passage of the virus in embryonated eggs. Such the new CAA virus and a method for producing the virus are also provided. The CAA virus can be proliferated in a high titer in vitro, and the obtained viruses hold immunogenicity and has extremely low pathogenicity. Thereby, the vaccine is effective for protecting fowls against CAA.  <P>COPYRIGHT: (C)2007,JPO&INPIT
For condition 1b, 600 or 1200 pulses of iTBS. iTBS will be administered at 80% of each participant's RMT in a burst-firing pattern (3 pulses at 50 Hz) for a 2 s train, followed by an 8 s period of rest. Across sessions, participants will receive one of two iTBS protocols (randomized): 600 pulses (190 s) or 1200 pulses (570 s).
CNS stimulants, including XELSTRYM, used to treat ADHD are associated with peripheral vasculopathy, including Raynaud's phenomenon. Signs and symptoms are usually intermittent and mild; however, sequelae have included digital ulceration and/or soft tissue breakdown. Effects of peripheral vasculopathy, including Raynaud's phenomenon, were observed in post-marketing reports and at the therapeutic dosage of CNS stimulants in all age groups throughout the course of treatment. Signs and symptoms generally improved after dosage reduction or discontinuation of the CNS stimulant. Careful observation for digital changes is necessary during XELSTRYM treatment. Further clinical evaluation (e.g., rheumatology referral) may be appropriate for XELSTRYM-treated patients who develop signs or symptoms of peripheral vasculopathy.
A biologically active oligosaccharide compound comprising at least two L hexose rings connected together by an ether oxygen atom. The ether oxygen atom is connected to a first of the rings at the first carbon atom to the right of the hexose ring oxygen atom. The com-pound contains at least one sulfate or phosphate group connected to the first ring at the third carbon atom to the right of the ring oxygen or to a methyl group at the fifth carbon atom to the right of the ring oxy-gen atom. The invention further includes the method for using the above oligosaccharide compound to detect .alpha. 1,3-L-fucosyltransferases or to block the activity of such .alpha. 1,3-L-fucosyltransferases or structureswhich mimic the structure of such fucosyltransferases to the extent that such structures bind to compounds of the present invention, e.g., as in the case of HIV virus.
The invention relates to a formulation of clobetasol propionate for topical use in the treatment of skin diseases such as atopic dermatitis and psoriasis. Said formulation has an excellent organoleptic appearance, very good therapeutic effect and favorable distribution in the stratum corneum. The liposomes include clobetasol propionate as active substance in low dose. Said liposomes are preferably stable and multilamellar vesicles, with an average size of 2000-5000 nm. The amount of active substance is preferably between 0.02 and 0.025 %. The pharmaceutical form of the product is preferably a jelly.
Infants and toddlers who are placed into foster or adoptive care often exhibit a number of behavioral, emotional, and physiological problems. In the absence of specialized services, problems in the relationship between caregiver and child may develop; problems in the child's functioning often persist and are exacerbated. This study will attempt to alleviate the attachment and regulatory difficulties that affect many young children placed into care.

Children are randomly assigned to either an experimental group or to a treatment control group for 3 years. The experimental group focuses on relational issues; the control group focuses on cognitive development. Caregivers receiving the relational intervention are trained to provide nurturing care, and to help children learn to develop adequate regulatory skills. Caregivers in the treatment control group receive training designed to enhance children's cognitive development. Caregivers in both groups will receive 10 home visits. Observations of children and parents are used to assess participants.
Moyamoya disease (MMD) is a chronic occlusive-stenosis cerebrovascular disease that characterized by the stenosis of internal carotid artery termination and the formation of net-like vessel. It is a multifactorial disease caused by genetic, inflammatory, immunological and other environmental factors. The specific pathogenesis of MMD is still unclear. The treatment modalities of revascularization and conservative management have been used in patients with MMD. However, the long-term outcomes of MMD with conservative management remain unknown. Also, some first-degree relatives who are carriers of genetic variants occasionally manifest with intracranial arterial stenosis. Therefore, it is significant to detect the long-term outcomes of conservative treatment in MMD patients and their first-degree relatives, and thus provide potential pathogenesis of MMD.
The objective of the study is to determine the effects of Multi-station Proprioceptive training on hamstring strains in Soccer Players. The study is a randomized controlled trial. Ethical approval is taken from ethical committee of Riphah International University, Lahore. Participants who meet the inclusion criteria will be enrolled and allocated in group A \& B through sealed envelope method by Non-probability Convenient random sampling technique. Group A will be the wobble board proprioceptive training program lasting for four weeks, while Group B will be administered the multi-station proprioceptive training program lasting for four weeks. Outcome measures will be assessed by using NPRS, Sit And Reach Test. Lower Extremity Functional Scale. Proximal Hamstring Injury Questionnaire. Balance Training Tool. The collected data will be analyzed in statistical Package for the social Sciences (SPSS) 25.0 .Parametric ∕non\|-parametric tests will be applied after test normality of data
PURPOSE: To obtain thiosalicylic acid bismuth complex and its salt having an excellent antibacterial action, especially a Helicobacter pylori-resistant action. CONSTITUTION: A bismuth compound (e.g. bismuth nitrate pentahydrate) is reacted with a mercapto group-having thiosalicyclic acid or 2-mercaptoethanol in a solvent (e.g. ethanol) at the ordinary temperature to a high temperature to obtain salicyclic acid bismuth complex or its salt, or 2-mercaptoethanol bismuth complex or its salt. Bismuth and salicyclic acid 2-mercaptoethanol are bound to each other in a ratio of 1:2, 1:3 or 2:3. The bismuth complex or its salt is added as an active ingredient to obtain the antibacterial agent. The antibacterial agent is especially useful for preventing or treating diseases caused by Helicobacter pylori. The administration amount of the active ingredient is 1-500mg per unit administration, and the active ingredient is administered in an unit administration amount of 0.25-500mg/individual body once-four times a day.
Large area deep burn patients, due to extensive skin defects in their limbs that cannot be repaired by the body itself, need to undergo skin grafting surgery to seal the wound. Although skin transplantation can partially meet the needs of wound sealing, the skin scar hyperplasia after transplantation and healing is significant, affecting the appearance and motor function of the limbs. Moreover, the healed skin lacks dermal tissue and sweat glands and other skin accessories, resulting in poor skin quality after wound healing, And accompanied by obvious discomfort such as fear of heat, itching, and pain, which seriously affects the patient's quality of life. Mesenchymal stem cells have high differentiation potential and can differentiate across embryonic boundaries into epithelial tissue cells such as skin. They can also secrete various cytokines to produce chemotactic and anti apoptotic effects, promoting the formation of wound neovascularization and wound healing. Human umbilical cord mesenchymal stem cells, due to their convenient and painless source, have become good seed cells for promoting wound healing.